New Drug to Lower 'Bad' Cholesterol Shows Promise
WebMD News Archive
Looking to the Future
Long-term data are needed and critical for further understanding, Gibbons says.
The need to inject the drug may not appeal to some patients, he says. "The inconvenience would be a barrier to many patients, particularly to those who don't have their own transportation."
Researchers need to examine whether the new drug results in fewer heart attacks and strokes.
Sanofi and Regeneron Pharmaceuticals are recruiting people for additional studies.
Amgen and other companies are also developing PCSK9 protein inhibitor drugs.